Investigator site selection is a critical element of a successful clinical trial. At Clinilabs Drug Development Corporation, we take pride in knowing our investigator sites first-hand. We build strong, positive relationships with our investigators, allowing us to have deep insight into study activity at their sites. We keep performance metrics on all investigators in order to provide sponsors with information regarding data quality, subject accrual rates, and GCP compliance at the investigator sites we recommend. In short, we know who enrolls, and we know the quality of the data they provide.
Remember the Three Princes of Serendip who went out looking for treasure? They didn’t find what they were looking for, but they kept finding things just as valuable. That’s serendipity, and our business [drugs] is full of it.
– George W. Merck